openPR Logo

Press Releases from Kuick Resarch (922 total)

Bispecific Antibody Drug Conjugates Development

The development of bispecific antibody drug conjugates (ADCs) marks a significant advancement in the field of targeted cancer therapy. These innovative molecules combine the specificity of bispecific antibodies with the powerful cytotoxic effects of drug conjugates, creating a new class of therapeutic agents that hold great promise for treating complex and resistant cancers. The process of developing these ADCs involves intricate design, engineering, and testing to ensure their safety, efficacy,

Breakthroughs in KRAS Inhibitor Research

KRAS mutations have posed a significant challenge in oncology for decades, but recent breakthroughs in KRAS inhibitor research have sparked hope for new cancer therapies. KRAS is a key regulator of cell growth and survival, and its mutations are prevalent in various cancers, particularly lung, colorectal, and pancreatic cancers. Despite being one of the most sought-after targets, KRAS has been notoriously difficult to inhibit, earning the reputation of being "undruggable." Download

Lumakras Drug Clinical Insight and Sales Forecast 2026

"Lumakras Drug Clinical Insight and Sales Forecast 2026" Report Highlights: * NSCLC Targeting Lumakras Market Opportunity (US$ Million) * Colorectal Cancer Targeting Lumakras Market Opportunity (US$ Million) * Pharmacokinetics of Lumakras (Sotorasib) * Dosage, Patent and Price Analysis * Lumakras Ongoing Clinical Trials * Global KRAS Protein Inhibitors Clinical Trials Download Report: https://www.kuickresearch.com/report-lumakras-sotorasib-sales-forecast-fda-approved-kras-inhibitor-clinical-trials-non-small-cell-lung-cancer-nslc-g12c-mutation-c30h30f2n6o3-ras-gtpase The rising burden of cancer and the increasing cancer mortality rates possesses an unmet need for the development of novel therapies in the management

Global EZH2 Inhibitor Market Opportunity, Sales and Clinical Trials Insight 2026

"Global EZH2 Inhibitor Market Opportunity, Sales and Clinical Trials Insight 2026" Report Highlights: * Global EZH2 Inhibitor Market Opportunity > US$ 1.2 Billion by 2026 * Tazverik (Tazemetostat) First Approved EZH2 Inhibitor Drug * Dosage, Price and Sales Analysis of Tazverik * Tazverik Sales Opportunity > US$ 900 Million by 2026 * Tazverik Sales Forecast 2021 Till 2026 * EZH2 Inhibitor Clinical Pipeline Overview By Company, Indication and Phase * EZH2 Inhibitor in Clinical Trials: 7 Drugs Download

Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Tr …

"Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Trials Insight 2028" Report Highlights: * Global Bispecific Antibody Market Opportunity: > US$ 20 Billion * Global Bispecific Antibody Market Growth Rate: 100% CAGR (2016 -2021) * Approved Bispecific Antibodies In Market: 4 Antibodies * Detailed Market Sales and Trends Insight Till 2028 * Quarterly and Yearly Sales Insight Of Approved Antibodies Till Q1 2022 * Global and Regional Market Analysis * Approved Drug Sales

Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and C …

"Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and Clinical Trials Insight 2026" Report Highlights: * Global FGFR Inhibitors Market Opportunity: > USD 4 Billion by 2026 * Role of FGFR Inhibitors in Cancer Therapy * Global FGFR Market Assessment (US$) by Region and Cancer Type Clinical and Sales Insight on Approved FGFR Inhibitors: 3 (Belvesra, Pemazyre and Truseltiq) * Dosage and Drug Price Insight on Approved FGFR Inhibitors * Comprehensive Clinical Trials Insight

Europe Biosimilars Market, Dosage, Price, Sales and Clinical Trials Insight 2026

"Europe Biosimilars Market, Dosage, Price, Sales and Clinical Trials Insight 2026" Report highlights: * Europe Biosimilars Market Opportunity: > USD 10 Billion * Dosage and Pricing insight On Approved Biosimilars * Biosimilars for Cancers Accounts for > 20% Market * Biosimilars for Diabetes Accounts for > 5% Market * Biosimilars Approval and Commercialization by Country * Insight On Biosimilar Clinical Trials By Company, Indication and Phase: > 100 Biosimilars * Insight On Commercially available Biosimilars in Market:

US Biosimilar Insulin Market Opportunity and Clinical Trials Insight 2026

"US Biosimilar Insulin Market Opportunity and Clinical Trials Insight 2026" Report Highlights: * US Diabetic Drug Market Opportunity: > US$ 35 Billion * US Insulin Market Opportunity > US$ 10 Billion * US Biosimilar Insulin Market Opportunity > US$ 1 Billion * US Biosimilar Insulin Market Cost Comparison Analysis * First FDA Approved Interchangeable Biosimilar Insulin Cost and Dosage Insight Download Report: https://www.kuickresearch.com/report-us-usa-united-states-biosimillar-inslin-fda-approved-semglee-glargine-interchangeable-biosimillar-market-sales-size-clinical-trials-mylan-pharmaceuticals Over the past few years, the acceptance of Biosimilars in US is increasing

Global Cell Therapy Market Outlook, Patent and Clinical Trials Insight 2028

"Global Cell Therapy Market Outlook, Patent and Clinical Trials Insight 2028" Report Highlights: * Global Cell Therapy Market Opportunity: > USD 45 Billion By 2028 * Cell Therapy Clinical Trial Insight by Indication, Company and Country * Insight On More than 1600 Cell Therapies in Clinical Trials * Clinical and Commercial Insight On 32 Cell Therapies Available in Market * Dosage and Pricing Insight By Country and Region * COVID-19 Impact Analysis on Global market

Global PDGFR Inhibitors Market, Drug Sales and Clinical Trials Insight 2026

Global PDGFR Inhibitors Market, Drug Sales and Clinical Trials Insight 2026 Report Analysis and Data Highlights: * Research Methodology * Global and Regional Market Analysis * Global PDGFR Inhibitors Market Opportunity Assessment: > USD 4 Billion * Market and Drug Sales Insight 2020 Till 2026 * Approved Drug In Market: 2 (Qinlock and Ayvakit) * Approved PGDFR Drug Patent, Price and Sales insight 2020 Till 2026 * Future market Assessment By Indication and Region Till 2026 * Ongoing

Global MEK Inhibitors Market, Drug Sales and Clinical Trials insight 2026

Global MEK Inhibitors Market, Drug Sales and Clinical Trials insight 2026 Report Analysis and Data Highlights: * Research Methodology * Global and Regional Market Analysis * Global MEK Inhibitors Market Opportunity Assessment: > USD 3 Billion * Market and Drug Sales Insight 2020 Till 2026 * Approved Drug In Market: 4 Drugs * Approved MEK Drug Patent, Price and Sales insight 2020 Till 2026 * Future Market Assessment By Indication Till 2026 * Ongoing Clinical Trials Assessment by

Ayvakit Patent, Sales and Clinical Trials Insight 2028

Ayvakit Patent, Sales and Clinical Trials Insight 2028 Report Analysis and Data Highlights: * Ayvakit Patent Insight * Ayvakit Dosage and Price * Ayvakit Sales Forecast 2028: > USD 1 Billion * Ayvakit Role in Cancer Therapy * Ayvakit Structure and Pharmacokinetics Properties * Ayvakit Ongoing Clinical Trials: > 10 Clinical Studies * Ayvakit Reimbursement Scenario Download Report: https://www.kuickresearch.com/report-ayvakit-avapritinib-sales-patent-market-clinical-trial Avapritinib (formerly BLU-285) developed by Blueprint Medicines Corporation is a selective and potent inhibitor of KIT and

Danyelza Patent, Sales and Clinical Trials Outlook 2028

Danyelza Patent, Sales and Clinical Trials Outlook 2028 Report Analysis and Data Highlights: * Danyelza Patent Insight * Danyelza Dosage and Price * Danyelza Sales Forecast 2028: > USD 400 Million * Danyelza Role in Neuroblastoma and Osteosarcoma Therapy * Danyelza Structure and Pharmacokinetics Properties * Danyelza Ongoing Clinical Trials: 10 Clinical Studies * Danyelza Reimbursement Scenario Download Report: https://www.kuickresearch.com/report-danyelza-sales-price-naxitamab-patent-sales-clinical-trials The introduction of more comprehensive, clinical grade sequencing platforms has promoted recognition of targetable genomic alterations

Rybrevant Bispecific Antibody Patent, Sales and Clinical Trials Outlook 2028

Rybrevant Bispecific Antibody Patent, Sales and Clinical Trials Outlook 2028 Report Analysis and Data Highlights: * Rybrevant Patent Insight * Rybrevant Dosage and Price * Rybrevant Sales Forecast 2028: > USD 4 Billion * Rybrevant Role in NSCLC and Other Cancer Therapies * Rybrevant Structure and Pharmacokinetics Properties * Rybrevant Ongoing Clinical Trials: > 5 Clinical Studies * Rybrevant Reimbursement Scenario Download Report: https://www.kuickresearch.com/report-rybrevant-amivantamab-price-sales-cost-market-patent-sales-clinical-trials-market The development of bispecific antibodies represents one of the most promising successes

Trikafta Patent, Sales and Clinical Trials Insight 2028

Trikafta Patent, Sales and Clinical Trials Insight 2028 Report Analysis and Data Highlights: * Trikafta Patent Insight * Trikafta Dosage and Price * Trikafta Sales Forecast 2028: > USD 5 Billion * Trikafta Chemistry and Pharmacokinetic Properties * Trikafta Ongoing Clinical Trials: > 15 Clinical Studies * Role in Cystic Fibrosis * Trikafta Reimbursement Scenario Download Report: https://www.kuickresearch.com/report-trikafta-patent-sales-clinical-trials-kaftrio-price-sales-cost-market-elexacaftor-ivacaftor-tezacaftor The successful mapping of human genome and advances in molecular technology has led to evolution of targeted therapies. The identification

Unituxin Patent, Sales and Clinical Trials Outlook 2028

Unituxin Patent, Sales and Clinical Trials Outlook 2028 Report Analysis and Data Highlights: * Unituxin Patent Insight * Unituxin Dosage and Price * Unituxin Sales Forecast 2028: > USD 500 Million * Unituxin Role in Cancer Therapy * Unituxin Structure and Pharmacokinetics Properties * Unituxin Ongoing Clinical Trials: > 10 Clinical Studies * Unituxin Reimbursement Scenario Download Report: https://www.kuickresearch.com/report-unituxin-dinutuximab-sales-price-cost-approvalpatent-sales-clinical-trials Neuroblastoma is an embryonic cancer of the post-ganglionic sympathetic nervous system. The treatment with conventional cancer therapies are

Trodelvy Patent, Sales and Clinical Trials Insight 2028

Trodelvy Patent, Sales and Clinical Trials Insight 2028 Report Analysis and Data Highlights: * Trodelvy Patent Insight: 29 Patents * Trodelvy Dosage and Price * Trodelvy Sales Forecast 2028: > USD 3 Billion * Trodelvy Role in Cancer Therapy * Trodelvy Structure and Pharmacokinetics Properties * Trodelvy Ongoing Clinical Trials: > 30 Clinical Studies * Trodelvy Reimbursement Scenario Download Report: https://www.kuickresearch.com/report-trodelvy-patent,-sales-clinical-trials-sacituzumab-govitecan-sales-market-price The worldwide prevalence of breast cancer is increasing rapidly

Global TRK Inhibitors Market, Drug Sales and Clinical Trials insight 2026

Global TRK Inhibitors Market, Drug Sales and Clinical Trials Insight 2026 Report Analysis and Data Highlights: * Research Methodology * Global and Regional Market Analysis * Global TRK Inhibitors Market Opportunity Assessment: > USD 2 Billion * Market and Drug Sales Insight 2020 Till 2026 * Approved Drug In Market: 2 Drugs * Approved TRK Drug Patent, Price and Sales insight 2020 Till 2026 * Future Market Assessment By Indication Till 2026 * Ongoing Clinical Trials Assessment by

Global B Cell Maturation Antigen (BCMA) Targeted Therapy Market and Clinical Tri …

Global B Cell Maturation Antigen (BCMA) Targeted Therapy Market and Clinical Trials Insight 2026 Report Analysis and Data Highlights: * Research Methodology * Global and Regional Market Analysis * Global BCMA Targeted Drugs Market Opportunity Assessment: > USD 4 Billion * Market and Drug Sales Insight 2020 Till 2026 * Approved Drug In Market: 2 Drugs * Approved BCMA Targeted Drugs Patent, Price and Sales insight 2020 Till 2026 * Future Market Assessment By Indication Till 2026 *

Global TROP2 Antibody Market and Clinical Trials Insight 2026

Global TROP2 Antibody Market and Clinical Trials Insight 2026 Report Analysis and Data Highlights: * Research Methodology * Global and Regional Market Analysis * Global TROP2 Antibody Market Opportunity Assessment: > USD 4 Billion * Market and Drug Sales Insight 2020 Till 2026 * Approved Drug In Market: 1 Drugs * Approved TROP2 Antibody Patent, Price and Sales insight 2020 Till 2026 * Future Market Assessment By Indication Till 2026 * Ongoing Clinical Trials Assessment by Status, Phase

Global Trispecific Antibody Market Opportunity and Clinical Trials Insight 2028

Global Trispecific Antibody Market Opportunity and Clinical Trials Insight 2028 Report Analysis and Data Highlights: * Research Methodology * Global Market Analysis * Global Trispecific Antibody Market Opportunity Assessment: > USD 2 Billion * US To Dominate Trispecific Antibodies Market: >70% * Market and Drug Sales Insight 2024 Till 2028 * Future Market Assessment By Indication Till 2028 * Ongoing Clinical Trials Assessment by Status, Phase and Region * Key Market Dynamics * Competitor Landscape Download Report: https://www.kuickresearch.com/report-trispecific-antibody-antibodies-market-clinical-trials-development-companies The advent

Global TIGIT Inhibitor Drug Opportunity and Clinical Research Insight 2022

Global TIGIT Inhibitor Drug Opportunity and Clinical Research Insight 2022 Report Highlights: * Global TIGIT Inhibitor Market Dynamics * Clinical Approaches to Target TIGIT * Role of TIGIT Inhibitors in Cancer, HIV, Autoimmune Disorders * Number of TIGIT Inhibitor Drug In Trials * TIGIT Inhibitors Trials By Phase, Company, Country, Indication * Clinical Trials Adverse Events Scenario * Company Agreement/Partnership/Deals For Ongoing Trials * Global TIGIT Inhibitor Market Future Outlook Download Report: https://www.kuickresearch.com/report-tigit-inhibitors-clinical-trials-market-antibodies-immune-checkpoint-cancer-immunotherapy T-cell immunoreceptor with Ig and

Global LAG 3 Inhibitor Clinical Trials and Market Opportunity Insight 2028

Global LAG 3 Inhibitor Clinical Trials and Market Opportunity Insight 2028 Report Highlights: * Global LAG 3 Inhibitors Market Dynamics * Clinical Approaches to Target LAG 3 Inhibitors * Number of LAG 3 Inhibitors Drug In Trials * LAG 3 Inhibitors Approved Patent Insight * LAG 3 Inhibitors Trials By Phase, Company, Country, Indication * Company Agreement/Partnership/Deals For Ongoing Trials * LAG-3 Targeted Approach in Cancer Therapy * Therapeutic Approaches for Novel LAG-3 Targeted Therapy * Global LAG 3

Global LAG 3 Inhibitor Clinical Trials and Market Opportunity Insight 2028

Global LAG 3 Inhibitor Clinical Trials and Market Opportunity Insight 2028 Report Highlights: * Global LAG 3 Inhibitors Market Dynamics * Clinical Approaches to Target LAG 3 Inhibitors * Number of LAG 3 Inhibitors Drug In Trials * LAG 3 Inhibitors Approved Patent Insight * LAG 3 Inhibitors Trials By Phase, Company, Country, Indication * Company Agreement/Partnership/Deals For Ongoing Trials * LAG-3 Targeted Approach in Cancer Therapy * Therapeutic Approaches for Novel LAG-3 Targeted Therapy * Global LAG 3

US Cancer Antibodies Market, Drug Sales, Patent and Clinical Trials Outlook 2028

US Cancer Antibodies Market, Drug Sales, Patent and Clinical Trials Outlook 2028 Report Highlights: * US Cancer Antibodies Market Opportunity: > US$ 85 Billion by 2028 * US Cancer Antibodies Market To Witness More Than 200% Absolute Growth * Current and Future market Projections by Drugs and Therapeutic Class * Clinical Trials Insight On by Company, Indication, Patient Segment and Phase * Immune Checkpoint Inhibitors Dominating The Antibodies Sales: > 15 Billion In 2021 * Insight

Global Transdermal Patch Market, Dosage, Price and Clinical Trials Insight 2028

Global Transdermal Patch Market, Dosage, Price and Clinical Trials Insight 2028 Report Highlights: * Research Methodology * Global and Regional Transdermal Path Market Outlook * Global Transdermal Patch Market Opportunity > USD 20 Billion * Clinical Trials Insight By Company, Indication, Drug Molecule and Phase * Comprehensive Insight On 60 Transdermal Patch Available Commercially * Comprehensive Insight On 80 Transdermal Patch In Clinical Trials By Phase * Transdermal Patch Dosage and Price Availability By Indication * Competitive Landscape

Global Cancer Antibody Drug Conjugate Market, Price, Dosage and Clinical Trials …

Global Cancer Antibody Drug Conjugate Market, Drug Sales, Price, and Clinical Trials Insight 2028 Report Highlights: * Global Cancer Antibody Drug Conjugate Market Opportunity > USD 25 Billion * Global Market Sales Trends and Market Forecast Till 2028 * Clinical Insight On 18 Approved Cancer Antibody Drug Conjugates * Dosage, Price and Patent Insight On 18 Cancer Antibody Drug Conjugate * Quarterly and Yearly Drug Sales Insight and Forecast Till 2028 * Clinical Insight On More

Global Immune Checkpoint Inhibitors Biomarkers and Clinical Trials Insight 2028

Global Immune Checkpoint Inhibitors Biomarkers and Clinical Trials Insight 2028 Report Highlights: * Global Immune Checkpoint Inhibitors Market Opportunity: > USD 30 Billion * Immune Checkpoint Inhibitors Clinical Trials Insight: CTLA-4, LAG3, PD-1/PD-L1, TIGIT Inhibitors * Immune Checkpoint Inhibitors Clinical Trials Insight: > 300 Drugs In Trials * Biomarkers Insight By Immune Checkpoint Inhibitors Classification * Insight On Biomarkers Sourced From Trials By Drugs and Indication * Biomarker Name and Function Insight By Immune Checkpoint

Global Nanoparticle Drug Delivery Market, Dosage, Price and Clinical Pipeline Ou …

Global Nanoparticle Drug Delivery Market, Dosage, Price and Clinical Pipeline Outlook 2028 Report Highlights: * Global Nanoparticle Drug Delivery Market Opportunity > USD 300 Billion by 2028 * Nanoparticle Drug Deliver Price and Dosage Insight By Therapeutic: Cancer, Anemia, Autoimmune Diseases, Neurological Disorders * Global Nanoparticle Drug Market Regional Analysis: US, Europe, China, Japan, India, Taiwan, South Korea, Canada * Nanoparticle Therapeutics Approved Drugs Sales Insight: 15 Drugs * Nanoparticle Therapeutics Approved Drugs

Home DNA Test Kit Market Opportunity Forecast 2028

Home DNA Test Kit Market Opportunity Forecast 2028 Report Highlights: * Global Home DNA Test Kit Market Opportunity > USD 10 Billion * US Dominating Global DNA Test Kit Market > 20% * Kits Availability and Price Analysis by Company, Country and Indication * Global Home Genetic Testing Kit Market by Application: Ancestry, Nutrigenomics, Parenting, Chronic Diseases * Global Home Genetic Testing Kit Market by Country: US, UK, china, India, Japan, South Korea, Taiwan, Singapore,

Global Bcr Abl Inhibitor Market, Drug Sales and Clinical Trials Insight 2028

Global Bcr-Abl Inhibitor Market, Drug Sales and Clinical Trials Insight 2028 Report Highlights: * Global Bcr-Abl Inhibitor Market Opportunity > USD 8 Billion * Approved Bcr-Abl Inhibitor Drugs: 8 Drugs * Global Bcr-Abl Inhibitor Market Regional Analysis and Forecast Till 2028 * Bcr-Abl Inhibitor Drug Market Past Sales and Future Forecast Till 2028 * Market Analysis By First, Second and Third Generation Approved drugs * Bcr-Abl Inhibitor Drug Prices, Dosage and Patent Insight * Global Bcr-Abl Inhibitor

Global KRAS Inhibitors Market and Clinical Trials Forecast 2028

"Global KRAS Inhibitors Market and Clinical Trials Forecast 2028" Report Highlights: * KRAS Inhibitors Market Opportunity: > USD 4.5 Billion by 2028 * Initially US To Dominate KRAS Inhibitors Market: >70% Market Share * Number of KRAS Inhibitors In Trials: > 45 Drugs * Number of Approved Drugs: 1 (Lumakras) * Lumakras Dosage, Sales, Patent and Price Insight * Solid Tumors Targeted Drugs Dominating The Clinical Trials * Global KRAS Inhibitors Market Trends and Dynamics * Global KRAS

Gamma Delta T Cell Cancer Therapy Market and Clinical Trials Forecast 2028

"Gamma Delta T Cell Cancer Therapy Market and Clinical Trials Forecast 2028" Report Highlights: * Commercialization Market Potential After Market Launch: > USD 4 Billion * Insight on Key Drugs In Research and Development * Global Gamma Delta T Cell Cancer Therapy Clinical Trials Insight * Gamma Delta T Cell Cancer Therapy In clinical Trials: > 15 Therapies * Gamma Delta T Cell Cancer Therapy Market Opportunity By Cancer Type * Adopted Approaches for Gamma Delta

Global PARP Inhibitors Cancer Therapy Market and Clinical Trials Insight 2028

Global PARP Inhibitors Cancer Therapy Market and Clinical Trials Insight 2028 Report Highlights: * Global PARP Inhibitors Cancer Therapy Market Opportunity: > USD 6 Billion * Commercially Available PARP inhibitors: > 5 Drugs * Comprehensive Clinical Insight On More Than 35 PARP Drug In Clinical Trials * Global PARP Clinical Trials Insight by Company, Country, Indication and Phase * Market Indicators Till 2028 * Approved Drugs Dosage, Sales, Patent, Price Insight * Approved Drugs Sales Forecast Till

Global Lymphoma Antibodies Market and Clinical Trials Insight 2028

"Global Lymphoma Antibodies Market and Clinical Trials Insight 2028" Report Highlights: * Global Lymphoma Antibodies Market Opportunity: >USD 5 Billion * Global Lymphoma Antibodies Market Insights: Current, Regional and Future Outlook 2028 * Annual, Quarterly and Regional Sales Insights On Lymphoma Antibodies * Lymphoma Antibodies Availability By Dosage, Patent, and Price Analysis * Clinical Insight On More Than 160 Lymphoma Antibodies In Trials * Lymphoma Antibodies Clinical Trials Insights by Company, Country and Phase * Annual,

Global CFTR Modulators Market Opportunity, Drug Sales and Clinical Trials Insigh …

Global CFTR Modulators Market Opportunity, Drug Sales and Clinical Trials Insight 2028 Report Insight: * Global CFTR Modulators Market Opportunity: > USD 25 Billion * Global CFTR Modulators Market Insights: Current, Regional and Future Outlook 2028 * Annual, Quarterly and Regional Sales Insights On CFTR Modulators * CFTR Modulators Availability By Dosage, Patent, and Price Analysis * Clinical Insight On More Than 30 CFTR Modulators In Trials * CFTR Modulators Clinical Trials Insight By Country,

Global CAR T Cell Therapy Market and Clinical Trials Insight 2028

Global CAR T Cell Therapy Market and Clinical Trials Insight 2028 Report Highlights: * Global CAR T Cell Therapy Market Opportunity > USD 15 Billion * Global and Regional Market Insight: Current and Market Forecast 2028 * Approved CAR T Cell Therapies Sales Forecast Till 2028 * Emerging In Vivo Induced CAR T Cell Therapies * CAR T Cell Therapy Manufacturing Cost Analysis * CAR T Cell Therapy Approval and Reimbursement Scenario By Country * Patent,

Global Orphan Drug Rare Disease Market Clinical Trials Forecast 2028

Global Orphan Drugs Clinical Trials Insight Report Highlights: • Clinical Insight On More Than 400 Marketed Orphan Drugs • Clinical Insight On More Than 1300 Orphan Drugs in Clinical Trials • Orphan Designated Drug Clinical Status by Indication & Country • Global Market Opportunity More Than USD 350 Billion • Market Exclusivity & Patent Protection Criteria for Orphan Drugs • Global & Regional Orphan Drug Market Sales Opportunity • Orphan Drug Reimbursement Policy • Orphan Clinical Pipeline Overview

Global CD233 Antibody Market Clinical Trials Intelligence 2028

Global CD233 Inhibitors Trials Intelligence Report Highlights: • Global CD233 Inhibitors Market Dynamics • Clinical Approaches to Target CD233 Inhibitors • Role of CD233 Inhibitors in Cancer, Autoimmune Disorders • Number of CD233 Inhibitors Drug In Trials • CD233 Inhibitors Approved Patent Insight • CD233 Inhibitors Trials By Phase, Company, Country, Indication • Company Agreement/Partnership/Deals For Ongoing Trials • Global CD233 Inhibitor Market Future Outlook For Report Sample Contact neeraj@kuickresearch.com The successful application of the anti-CTLA-4 and anti-PD-1/PD-L1

Global Gene Therapy Market Clinical Trials Research Insight 2028

Global Gene Therapy Market & Clinical Trials Intelligence Report Highlights • Global Market Gene Therapy Landscape USD 24 Billion Opportunity • Comprehensive Commercial & Clinical insight on 16 Approved Gene Therapies • Gene Therapy Products Dosage & Price Analysis • Comprehensive Clinical Insight On 1700 Gene Therapies In Clinical Trials • Information On 45 Orphan Designated Gene Therapies By Indication, Country, Company • Global Gene Therapy Clinical Trials Insight By Phase, Country, Formulations, Company, Indication, Target •

TROP2 Targeted Therapy Trodelvy Market Clinical Trials Insight 2026

Global TROP2 Antibody Market & Clinical Trials Insight 2026 Report Analysis and Data Highlights: • Research Methodology • Global & Regional Market Analysis • Global TROP2 Antibody Market Opportunity Assessment: > USD 4 Billion • Market and Drug Sales Insight 2020 Till 2026 • Approved Drug In Market: 1 Drugs • Approved TROP2 Antibody Patent, Price and Sales insight 2020 Till 2026 • Future Market Assessment By Indication Till 2026 • Ongoing Clinical Trials Assessment by Status, Phase & Region • Key Market Dynamics • Competitor Landscape Download Report:

Global Fibroblast Growth Factor Receptor FGFR Cancer Therapy Market Clinical Tri …

Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and Clinical Trials Insight 2026 Report Highlights: • Global FGFR Inhibitors Market Opportunity: > USD 4 Billion by 2026 • Role of FGFR Inhibitors in Cancer Therapy • Global FGFR Market Assessment (US$) by Region and Cancer Type • Clinical and Sales Insight on Approved FGFR Inhibitors: 3 (Belvesra, Pemazyre and Truseltiq) • Dosage and Drug Price Insight on Approved FGFR Inhibitors • Comprehensive Clinical Trials Insight by Company, Country, Phase and

Clinical Trials Advances And Challenges in Bispecific and Trispecific Antibodies …

In recent years, healthcare sector has witnessed emergence of several promising multispecific antibodies which have revolutioned the management of several chronic disorders, including cancer. Multispecific antibodies consist of large family of molecules which recognizes trwo or more different antigens or epitopes. The robust idea of multispecific antibodies has led to the development of several bispecific and trispecific antibodies for the treatment of cancer and other diseases. Till date, three bispecific

Global CFTR Modulators Market Opportunity Clinical Trials Insight 2026

“Global CFTR Modulators Market Opportunity, Dosage, Price & Clinical Trials Insight 2026” Report Highlights: • Global CFTR Modulators Market Opportunity: > US$ 20 Billion • Global CFTR Modulators Market Growth: 42% CAGR (2017 -2020) • Global CFTR Modulators Market Growth In 2020: 55% • Global CFTR Modulators Pipeline: 30 Drug • Commercially Available Bispecific Antibodies: 4 Drugs • Trikafta Market Share 2020: > 50% Download Report: https://www.kuickresearch.com/report-global-cystic-fibrosis-cftr-modulators-therapeutics-market-size-vertex-trikafta-cftr-potentiators-clinical-trials-research “Global CFTR Modulators Market Opportunity, Dosage, Price & Clinical Trials Insight 2026” provides

Gamma Delta T Cell Cancer Therapy Opportunity Clinical Trials Insight 2026

“Gamma Delta T Cell Cancer Therapy Opportunity & Clinical Trials Insight 2026” Report Highlights: • Commercialization Market Potential After Market Launch: > USD 4 Billion • Insight on Key Drugs In Research & Development • Global Gamma Delta T Cell Cancer Therapy Clinical Trials Insight • Gamma Delta T Cell Cancer Therapy In clinical Trials: > 15 Therapies • Gamma Delta T Cell Cancer Therapy Market Opportunity By Cancer Type • Adopted Approaches for Gamma Delta T Cell Therapy Download

Global Peptide Drug Conjugate Clinical Trial Report 2026

Global Peptide Drug Conjugate Market & Clinical Trials Insight 2026 Report Highlights: • First FDA Approved Peptide Drug Conjugate: Pepaxto (Melphalan Flufenamide) • Pepaxto Clinical & Commercial Insight: Dosage, Patent, Price, Sales Forecast • Peptide Drug Conjugate Sales Opportunity: US, Europe, Japan & South Korea • Global Peptide Drug Conjugate Clinical Pipeline: > 20 Drugs • Clinical Trials Insight by Company, Country, Indication • Patent Insight of Peptide Drug Conjugates • Profile & Clinical Pipeline Insight of Companies Developing Peptide Drug Conjugates Download Report: https://www.kuickresearch.com/report-global-peptide-drug-conjugate-antibodies-antibody-market-pepaxto-melphalan-flufenamide-melflufen-clinical-trials-fda-approved-oncology-cancer-peptide-clinical-pipeline “Global Peptide

Global Trispecific Antibodies Market Opportunity & Clinical Trials Insight 2024

"Global Trispecific Antibodies Market Opportunity & Clinical Trials Insight 2024" Report Highlights: • Commutative Market Opportunity During Initial 5 years of Commercialization: > US$ 2 Billion • Trispecific Antibodies In Clinical Trials: > 8 Antibodies • Highest Phase of Development: Phase I/II • Cancer Dominating Trispecific Antibodies Trials: > 5 Antibodies • Numab Therapeutics Dominating the Trispecific Development Pipeline • Prevention & Second Line Therapy Key Focus of Development of Trispecific Antibodies Download Report: https://www.kuickresearch.com/report-global-trispecific-antibodies-antibody-market-sales-size-companies-cancer-trispecific--clinical-trials-sar441236--development-conjugate-immunogenicity Trispecific cancer antibody therapy market at

Global BiTE Antibodies Market, Price, Sales & Clinical Trials Insight 2025

"Global BiTE Antibodies Market, Price, Sales & Clinical Trials Insight 2025" Report Highlights: • Global BiTE Antibody Market Opportunity Insight (2021-2025) • Currently Only 1 BiTE Commercially Available In Market: Blinatumomab (Blincyto) • Blincyto Dosage & Market Sales Analysis ( Yearly, Quarterly & Regional Sales) • Global BiTE Antibody Clinical Trials Indicators by Phase, Company, Country, Indication & Patient Segment • Global Bispecific T-Cell Engagers Market Dynamics Download Report: https://www.kuickresearch.com/report-global-bite-antibodies-blinatumomab-antibody-immunology-anticancer-market-sales-size-growth-forecast-price-cost-amgen-bispecific-t-cell-engager The research report, "Global BiTE Antibodies Market , Price, Sales &

Global BCL-2 (B Cell Lymphoma 2) Inhibitors Market & Clinical Trials Insight 202 …

"Global BCL-2 (B Cell Lymphoma 2) Inhibitors Market & Clinical Trials Insight 2025" Report Highlights: • Global BCL-2 Inhibitors Market Opportunity: >US$ 4 Billion by 2025 • Insight on Market Indicators & Approved Drugs Sales Data • Global BCL-2 Inhibitors Market Absolute Growth: >300% ( 97% CAGR, 2018 - 2020) • Comprehensive Information On Ongoing Clinical Trials • Global BCL-2 inhibitors Clinical Trials By Company, Indication & Phase • Venetoclax Is The First Approved Drug Belonging To The Class Of BCL2

Global Antibody Drug Conjugate Market Sales Size Opportunity To Surpass US$ 10 B …

"Novel Cancer Antibody Drug Conjugates to Drive Cancer Therapeutics Market With More Than 290 Cancer Antibodies In Clinical Trials Pipeline Says Kuick Research" "Global Cancer Antibody Drug Conjugate Market, Price, Dosage & Clinical Trials Insight 2026" Report Highlights: • Global Cancer Antibody Drug Conjugate (ADC) Pipeline: 297 Drugs • Marketed Cancer Antibody Drug Conjugate: 9 Drugs • Antibody Drug Conjugate Marketed Opportunity: > US$ 13 Billion By 2026 • Majority of Drug Trials Are For Second Line Therapy

Go To Page:   1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19